John Ford

John Ford has a diverse work experience in the biopharmaceutical industry. John is currently the Executive Chairman at ARMGO Pharma, where they oversee the development of a new class of drugs for cardiac, musculoskeletal, and neurological disorders. Prior to this, they served as the Chairman of Complement Therapeutics.

From 2016 to 2022, John Ford was the CEO of Enterprise Therapeutics, where they focused on developing muco-regulatory therapies for respiratory diseases. During their tenure, they successfully sold the TMEM16A portfolio to Roche/Genentech.

Before that, John Ford was the Co-Owner & Investor Director at Metrion Biosciences, a UK-based Contract Research Organization specializing in ion channel screening services. John also co-founded and served as the CEO of Ario Pharma, which developed TRPV1 inhibitors for Type 2 Diabetes.

John Ford's earlier experience includes co-founding Xention Discovery, where they worked as the CSO and focused on developing therapies for atrial fibrillation. John also held the position of General Manager UK Operations at AKARNA THERAPEUTICS, LTD, which was later acquired by Allergan.

John Ford's industry experience extends back to 1998, where they served as a Team Leader at BioFocus Discovery Ltd, focusing on cell-based drug discovery campaigns.

John Ford attended Robert Smyth Grammar School from 1988 to 1992. After completing their secondary education, they enrolled at the University of Leeds. From 1992 to 1998, they pursued a Bachelor of Science degree in Biochemistry & Pharmacology, earning a first-class distinction. Subsequently, they continued their studies at the University of Leeds and completed their Doctor of Philosophy (PhD) in the same field.